Patterns of tocilizumab use, effectiveness and safety in patients with rheumatoid arthritis: Core data results from a set of multinational observational studies

Clinical and Experimental Rheumatology

Volumn 35, Issue 6, 2017, Pages 0899-0906

  Haraoui, Bolous ^a   Casado, Gustavo ^b   Czirják, Laszlo ^c   Taylor, Andrew ^d   Bernasconi, Corrado ^e   Reiss, William ^e   Caporali, Roberto ^f  

^a Institut de Rhumatologie   (Canada)

^b HOSPITAL MILITAR CENTRAL   (Argentina)

^c UNIVERSITY OF PÉCS   (Hungary)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

^f UNIVERSITY OF PAVIA   (Italy)

Author keywords

Anti rheumatic drugs; Biologic factors; Humanised monoclonal antibodies; Rheumatoid arthritis

Indexed keywords

CORTICOSTEROID; CYCLOSPORINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE; TOCILIZUMAB; IL6R PROTEIN, HUMAN; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY;

ABNORMAL LABORATORY RESULT; ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL DISEASE ACTIVITY INDEX; CLINICAL PRACTICE; COMBINATION DRUG THERAPY; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HEART ARRHYTHMIA; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; INFECTION; INFESTATION; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUTROPENIA; OBSERVATIONAL STUDY; PANCYTOPENIA; PATIENT COMPLIANCE; PNEUMONIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SEPSIS; SHOCK; SIDE EFFECT; SKIN DISEASE; THROMBOCYTOPENIA; TREATMENT DURATION; AGED; CLINICAL TRIAL; IMMUNOLOGY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDNISONE; RECEPTORS, INTERLEUKIN-6;

EID: 85034712308     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. SMOLEN JS, LANDEWE R, BREEDVELD FC et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73: 492-509
2. SINGH JA, SAAG KG, BRIDGES SL Jr et al.: 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res 2016; 68: 1-25
3. SOLIMAN MM, ASHCROFT DM, WATSON KD, LUNT M, SYMMONS DP, HYRICH KL: Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011; 70: 583-9
4. PAPPAS DA, REED GW, SAUNDERS KC et al.: Characteristics associated with biologic initiation as monotherapy versus combination therapy in patients with rheumatoid arthritis (RA) in a US registry Population [abstract]. Arthritis Rheum 2012; 64 (Suppl. 10): S557
5. NISHIMOTO N, YOSHIZAKI K, MAEDA K et al.: Toxicity, pharmacokinetics, and dosefinding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis: phase I/ II clinical study. J Rheumatol 2003; 30: 1426-35
6. DAYER JM, CHOY E: Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology 2010; 49: 15-24
7. HOUSSIAU FA, DEVOGELAER JP, van DAMME J, de DEUXCHAISNES CN, van SNICK J: Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988; 31: 784-8
8. GOTTENBERG JE, DAYER JM, LUKAS C et al.: Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort. Ann Rheum Dis 2012; 71: 1243-8
9. Genentech, Inc.: ACTEMRA® (tocilizumab) injection, for intravenous use injection, for subcutaneous use [prescribing information]. South San Francisco, CA: Genentech, Inc.; November 2014
10. Roche Registration Limited: RoActemra 20 mg/ml concentrate for solution for infusion. Welwyn Garden City, UK: Roche Registration Limited; 2014
11. SMOLEN JS, BEAULIEU A, RUBBERT-ROTH A et al.: Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a doubleblind, placebo-controlled, randomised trial. Lancet 2008; 371: 987-97
12. GENOVESE MC, McKAY JD, NASONOV EL et al.: Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58: 2968-80
13. EMERY P, KEYSTONE E, TONY HP et al.: IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebocontrolled trial. Ann Rheum Dis 2008; 67: 1516-23
14. FLEISCHMANN RM, HALLAND AM, BRZOSKO M et al.: Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results. J Rheumatol 2013; 40: 113-26
15. JONES G, SEBBA A, GU J et al.: Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010; 69: 88-96
16. GABAY C, EMERY P, van VOLLENHOVEN R et al.: Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013; 381: 1540-1
17. DOUGADOS M, KISSEL K, CONAGHAN PG et al.: Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis 2014; 73: 803-9
18. BURMESTER GR, RIGBY WF, van VOLLENHOVEN RF et al.: Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis 2016; 75: 1081-91
19. BYKERK VP, OSTOR AJ, ALVARO-GRACIA J et al.: Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice. Clin Rheumatol 2015; 34: 563-71
20. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24
21. CHOY EH, BERNASCONI C, AASSI M et al.: Treatment of rheumatoid arthritis with an anti-tumor necrosis factor agent or tocilizumab as first biologic therapy in a global comparative observational study [abstract]. Arthritis Rheumatol 2015; 67 (Suppl. 10)
22. DOUGADOS M, KISSEL K, SHEERAN T et al.: Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2 year randomized controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013; 72: 43-50
23. KONCZ T, PENTEK M, BRODSZKY V, ERSEK K, ORLEWSKA E, GULACSI L: Adherence to biologic DMARD therapies in rheumatoid arthritis. Expert Opin Biol Ther 2010; 10: 1367-78
24. SCHIFF MH, KREMER JM, JAHREIS A, VERNON E, ISAACS JD, van VOLLENHOVEN RF: Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011; 13: R141
25. WEINBLATT ME, KREMER J, CUSH J et al.: Tocilizumab as monotherapy or in combination with nonbiologic DMARDs: 24-week results of an open-label, clinical practice study (ACT-STAR). Arthritis Care Res 2011; 13: 362-71